MCID: NRV006
MIFTS: 59

Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Nervous System Cancer

MalaCards integrated aliases for Nervous System Cancer:

Name: Nervous System Cancer 12 14
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm 69
Malignant Neoplasm of Nervous System 12
Neoplasm of the Nervous System 29
Tumor of the Nervous System 12
Neoplasm of Nervous System 12
Nervous System Neoplasms 69
Nervous System Neoplasm 12
Neoplasms, Nerve Tissue 42
Nervous System--Cancer 69
Nervous System Tumor 52
Neural Neoplasm 12
Neural Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3093
ICD9CM 35 192 192.9
MeSH 42 D009380
NCIt 47 C35562
SNOMED-CT 64 188306000

Summaries for Nervous System Cancer

Disease Ontology : 12 An organ system cancer located in the nervous system that affects the central or peripheral nervous system.

MalaCards based summary : Nervous System Cancer, also known as neuroepithelial, perineurial, and schwann cell neoplasm, is related to olfactory neural tumor and autonomic nervous system neoplasm. An important gene associated with Nervous System Cancer is NF1 (Neurofibromin 1), and among its related pathways/superpathways are ERK Signaling and Cell Cycle, Mitotic. The drugs Menthol and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Nervous System Cancer

Diseases in the Nervous System Cancer family:

Nervous System Benign Neoplasm

Diseases related to Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
id Related Disease Score Top Affiliating Genes
1 olfactory neural tumor 34.2 CDKN2A ENO2 TP53
2 autonomic nervous system neoplasm 34.1 CCND1 CDKN1A CDKN2A CDKN2B RB1 TP53
3 neuroblastoma 30.2 BACE1 CASP3 ENO2 MYC MYCN TP53
4 phalangeal microgeodic syndrome 11.1 MYCN RB1
5 neurofibromatosis-noonan syndrome 11.1 NF1 NF2
6 brain stem astrocytic neoplasm 11.1 NF1 TP53
7 lung lymphoma 11.1 CALCA NF1 NF2
8 ependymoma 11.0
9 rnase t2-deficient leukoencephalopathy 11.0 CDK4 TP53
10 cervical keratinizing squamous cell carcinoma 11.0 CALCA ENO2 NF1
11 cervical adenoid cystic carcinoma 11.0 CDKN2A TP53
12 extraocular retinoblastoma 11.0 MYCN RB1 RBL1
13 demyelinating disease 11.0 ENO2 NF1 NF2
14 ascaridiasis 11.0 CDK4 NF2 TP53
15 skeletal tuberculosis 11.0 CCND1 CDKN2A
16 penis paget's disease 11.0 CDKN2A CDKN2B TP53
17 renal pelvis urothelial papilloma 11.0 NF2 TP53
18 diphtheria 11.0 ENO2 NF1 NF2
19 epidural abscess 11.0 ENO2 NF1 NF2
20 juxtacortical chondrosarcoma 11.0 CDK4 CDKN2A RB1
21 secondary pulmonary hemosiderosis 11.0 CDK4 CDKN2A TP53
22 verruciform xanthoma of skin 10.9 ENO2 NF2
23 kidney hypertrophy 10.9 CDKN2A NF1 NF2
24 rhizomelic chondrodysplasia punctata, type 3 10.9 CASP3 TP53
25 cervical adenomyoma 10.9 ENO2 NF1 TP53
26 toxic pneumonitis 10.9 ENO2 NF2 TP53
27 childhood medulloblastoma 10.9 ENO2 MYCN TP53
28 hypoglossal nerve neoplasm 10.9 ENO2 NF1 NF2
29 pharynx carcinoma in situ 10.9 ENO2 MYC MYCN
30 tracheal disease 10.9 CASP3 CDKN2A TP53
31 benign pleural mesothelioma 10.9 CDKN2A CDKN2B NF1 NF2
32 bladder squamous cell carcinoma 10.9 CCND1 CDKN2A TP53
33 ossifying fibromyxoid tumor 10.9 CDK4 ENO2 TP53
34 pancreatic agenesis 10.9 CDKN2A ENO2 TP53
35 neurofibroma of the esophagus 10.9 CCND1 CDK4 CDKN2A
36 fallopian tube adenomatoid tumor 10.9 CDKN1A ENO2 MYCN
37 accelerated tumor formation 10.9 BACE1 CASP3
38 internal auditory canal lipoma 10.9 CDKN2A ENO2 TP53
39 c-p angle neurinoma 10.9 CDKN2A NF1 NF2 TP53
40 gastrointestinal neuroendocrine tumor 10.9 CCND1 CDKN2A TP53
41 skin hemangioma 10.9 MYC MYCN TP53
42 ductal carcinoma in situ 10.9 CCND1 CDKN2A TP53
43 middle ear squamous cell carcinoma 10.9 CDKN2A ENO2 TP53
44 villous adenocarcinoma 10.9 CDKN2A MYC TP53
45 peritoneal benign neoplasm 10.9 ENO2 NF1 NF2 TP53
46 connective tissue cancer 10.9 CALCA ENO2 NF2
47 acute cholinergic dysautonomia 10.9 CDKN1A TP53
48 vestibular gland benign neoplasm 10.9 ENO2 NF1 NF2 TP53
49 brachyolmia 10.9 CALCA ENO2 TP53
50 prostate transitional cell carcinoma 10.9 CASP3 CCND1 RB1 TP53

Graphical network of the top 20 diseases related to Nervous System Cancer:



Diseases related to Nervous System Cancer

Symptoms & Phenotypes for Nervous System Cancer

GenomeRNAi Phenotypes related to Nervous System Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.8 TP53 CASP3 CDK2 CDKN1A CDKN2A RB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.8 CASP3 CCND1 CDK2 CDKN1A CDKN2A MYC
3 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 CDK2 CDK4 ENO2 MYCN RBL1

MGI Mouse Phenotypes related to Nervous System Cancer:

44 (show all 27)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.55 RB1 RBL1 TP53 BACE1 CASP3 CCND1
2 behavior/neurological MP:0005386 10.51 BACE1 CASP3 CCND1 CDK4 CDKN1A CDKN2A
3 growth/size/body region MP:0005378 10.49 CDK4 CDKN1A CDKN2A ENO2 MYC MYCN
4 homeostasis/metabolism MP:0005376 10.47 TP53 BACE1 BCHE CASP3 CCND1 CDK2
5 mortality/aging MP:0010768 10.44 BACE1 BCHE CASP3 CCND1 CDK2 CDK4
6 hematopoietic system MP:0005397 10.42 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
7 cardiovascular system MP:0005385 10.41 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
8 endocrine/exocrine gland MP:0005379 10.41 CDK2 CDK4 CDKN1A CDKN2A CDKN2B MYC
9 integument MP:0010771 10.39 BACE1 CASP3 CCND1 CDK2 CDK4 CDKN1A
10 embryo MP:0005380 10.38 NUMBL RB1 RBL1 TP53 CDK2 CDK4
11 immune system MP:0005387 10.37 CDK2 CDK4 CDKN1A CDKN2A CDKN2B MYC
12 craniofacial MP:0005382 10.36 CASP3 CCND1 CDKN1A ENO2 MYC MYCN
13 digestive/alimentary MP:0005381 10.35 CASP3 CCND1 CDK4 CDKN1A CDKN2A MYC
14 nervous system MP:0003631 10.33 BACE1 CASP3 CCND1 CDK4 CDKN1A CDKN2A
15 neoplasm MP:0002006 10.29 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
16 muscle MP:0005369 10.27 TP53 BACE1 CASP3 CDK2 CDK4 CDKN1A
17 liver/biliary system MP:0005370 10.26 MYC MYCN NF1 NF2 RB1 RBL1
18 hearing/vestibular/ear MP:0005377 10.24 CASP3 CDKN1A MYC NF1 NF2 NUMBL
19 no phenotypic analysis MP:0003012 10.13 CDKN2B MYC MYCN RB1 RBL1 TP53
20 reproductive system MP:0005389 10.13 BCHE CASP3 CCND1 CDK2 CDK4 CDKN1A
21 normal MP:0002873 10.1 RB1 RBL1 TP53 BACE1 CCND1 CDK4
22 limbs/digits/tail MP:0005371 10.08 CDKN1A MYC MYCN NF1 RB1 RBL1
23 renal/urinary system MP:0005367 10.02 CASP3 CDK4 CDKN1A CDKN2B MYCN NF1
24 pigmentation MP:0001186 9.91 CASP3 CDK4 CDKN2A MYC NF1 RB1
25 respiratory system MP:0005388 9.9 CDKN1A CDKN2A ENO2 MYCN NF1 NF2
26 skeleton MP:0005390 9.7 CASP3 CCND1 CDKN1A CDKN2A MYC MYCN
27 vision/eye MP:0005391 9.4 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A

Drugs & Therapeutics for Nervous System Cancer

Drugs for Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1106)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-23-7 5754 657311
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
4
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 6740-88-1 3821
5
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
6
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 76631-46-4, 113775-47-6 68602 5311068 56032
7
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 57-27-2 5288826
8
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
9
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-43-4 5816
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 437-38-7 3345
11
Ketorolac Approved Phase 4,Phase 3,Early Phase 1 74103-06-3, 66635-83-4 3826
12
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2078-54-8 4943
13 Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14
Budesonide Approved Phase 4,Phase 2,Phase 1 51333-22-3 63006 5281004
15
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
16
Terbutaline Approved Phase 4 23031-25-6 5403
17
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
18
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
19
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 137-58-6 3676
20
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
21
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
22
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
23
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
24
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
25
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
26
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
27
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 28523-86-6 5206
28
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 1 466-99-9 5284570
29
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Early Phase 1 15687-27-1 3672
30
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 76-42-6 5284603
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
32
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
33
Hydralazine Approved Phase 4,Phase 3,Phase 2,Phase 1 86-54-4 3637
34
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 83150-76-9 383414 6400441
35
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
36
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 216974-75-3
37
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 7487-88-9 24083
38
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2 465-65-6 5284596
39
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
40
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
42
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 23214-92-8 31703
43
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
44
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
45
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
46
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
47
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
48
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
49
Tramadol Approved, Investigational Phase 4,Phase 2 27203-92-5 33741
50
Codeine Approved, Illicit Phase 4 76-57-3 5284371

Interventional clinical trials:

(show top 50) (show all 3857)

id Name Status NCT ID Phase Drugs
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy Unknown status NCT00129597 Phase 4 ketalar
4 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4 paracetamol;placebo tablets
5 A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain Unknown status NCT02289261 Phase 4 Morphine;Morphine plus dexmedetomidine
6 Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia Unknown status NCT02103946 Phase 4
7 Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients Unknown status NCT01189409 Phase 4 PEG then Senna;Senna then PEG
8 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
9 The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study Unknown status NCT02385656 Phase 4 Modafinil
10 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
11 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
12 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
13 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
14 DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor Completed NCT00029523 Phase 4 Intrathecal (injected into the spinal fluid) DepoCyt;Intrathecal methotrexate;Intrathecal cytarabine (also known as ara-C)
15 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
16 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
17 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
18 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
19 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
20 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
21 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
22 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
23 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
24 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
25 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
26 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
27 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
28 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
29 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
30 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
31 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Completed NCT00169611 Phase 4 methylphenidate
32 Modafinil for the Treatment of Fatigue in Lung Cancer V9.0 Completed NCT00829322 Phase 4 Modafinil;Placebo
33 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
34 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
35 A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
36 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
37 Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesamet™ (nabilone)
38 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
39 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
40 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4 Hydromorphone
41 LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
42 Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer Completed NCT00638599 Phase 4
43 PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain Completed NCT01719757 Phase 4 Oxycodone/Naloxone
44 An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain Completed NCT00771199 Phase 4 Transdermal Therapeutic System (TTS)-Fentanyl
45 Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients Completed NCT01621100 Phase 4 OROS hydromorphone
46 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4 Hydromorphone HCl OROS
47 A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain Completed NCT01968018 Phase 4 Tramadol HCI/acetaminophen
48 RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder. Completed NCT01809106 Phase 4 Morphine;Fentanyl;Buprenorphine;Oxycodone
49 Effect of Eszopiclone on Sleep Disturbance and Pain in Cancer Completed NCT00365261 Phase 4 Eszopiclone;Placebo
50 An Interventional Study for Patients With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through IV Continuous Infusion Completed NCT02660229 Phase 4 Oxycodone Hydrochloride;Morphine Sulphate

Search NIH Clinical Center for Nervous System Cancer

Cochrane evidence based reviews: neoplasms, nerve tissue

Genetic Tests for Nervous System Cancer

Genetic tests related to Nervous System Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Nervous System 29

Anatomical Context for Nervous System Cancer

MalaCards organs/tissues related to Nervous System Cancer:

39
Brain, Breast, Lung, Prostate, Pituitary, Bone, T Cells

Publications for Nervous System Cancer

Articles related to Nervous System Cancer:

(show all 24)
id Title Authors Year
1
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
2
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
3
Stat Bite Number of New Brain and Other Nervous System Cancer Cases By Race/Ethnicity & Sex (2008-2012). ( 26538626 )
2015
4
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
5
Five-year relative survival rate of brain and other nervous system cancer in the USA, Europe and Japan. ( 25717112 )
2015
6
Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. ( 25483452 )
2015
7
Identification of miRNAs as potential new biomarkers for nervous system cancer. ( 25139093 )
2014
8
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
9
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
10
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
11
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
12
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
13
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
14
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. ( 19920894 )
2009
15
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
16
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. ( 18338171 )
2008
17
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
18
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
19
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
20
Nervous system cancer mortality in an industrialized area of Brazil 1980-1993. ( 10920400 )
2000
21
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
22
Risk of nervous system cancer among workers exposed to lead. ( 8673517 )
1996
23
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
24
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982

Variations for Nervous System Cancer

Expression for Nervous System Cancer

Search GEO for disease gene expression data for Nervous System Cancer.

Pathways for Nervous System Cancer

Pathways related to Nervous System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
2
Show member pathways
13.54 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
3
Show member pathways
12.85 CASP3 CDKN1A CDKN2A MYC TP53
4
Show member pathways
12.83 CASP3 CCND1 CDK2 CDK4 TP53
5 12.83 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
6
Show member pathways
12.82 CCND1 CDK2 CDK4 CDKN1A MYC RB1
7 12.77 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
8 12.68 BACE1 CALCA ENO2 MYCN NF1 NF2
9 12.67 CCND1 CDK2 CDK4 CDKN1A CDKN2A RB1
10
Show member pathways
12.66 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
11 12.64 CASP3 CCND1 CDKN1A CDKN2A MYC TP53
12 12.6 CCND1 CDK2 CDK4 MYC RB1 RBL1
13
Show member pathways
12.59 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
14 12.57 CCND1 CDK4 CDKN1A CDKN2A CDKN2B MYC
15
Show member pathways
12.45 CCND1 CDK2 CDK4 RB1
16
Show member pathways
12.45 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
17
Show member pathways
12.43 CCND1 CDKN1A MYC TP53
18
Show member pathways
12.42 CASP3 CCND1 CDK2 CDK4 CDKN1A RB1
19 12.41 CDK2 CDKN1A MYC RB1 TP53
20 12.41 CASP3 CCND1 CDKN1A MYC TP53
21
Show member pathways
12.41 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
22
Show member pathways
12.4 CASP3 CCND1 CDK2 CDK4 CDKN1A MYC
23
Show member pathways
12.38 CDK2 CDKN1A RB1 TP53
24 12.38 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
25
Show member pathways
12.37 CCND1 CDK2 CDK4 CDKN1A CDKN2A CDKN2B
26
Show member pathways
12.35 CCND1 CDKN1A MYC TP53
27 12.31 CASP3 CCND1 CDKN1A MYC TP53
28 12.29 CDKN1A MYC MYCN TP53
29 12.28 CASP3 CCND1 CDK2 CDK4 MYC NF1
30 12.26 CASP3 CCND1 CDK2 CDK4 CDKN1A CDKN2A
31 12.24 CCND1 CDKN1A CDKN2B MYC RBL1 TP53
32 12.24 CCND1 CDK2 CDK4 CDKN1A CDKN2A TP53
33 12.18 CDK2 CDKN1A CDKN2A RB1 TP53
34 12.17 CASP3 CCND1 CDK2 CDK4 MYC RB1
35
Show member pathways
12.16 CCND1 CDK2 CDKN1A CDKN2B
36
Show member pathways
12.14 CCND1 CDK2 CDK4 NF1
37 12.13 CCND1 CDKN1A CDKN2A MYC TP53
38 12.08 CCND1 CDKN1A MYC TP53
39 12.04 CDKN1A CDKN2A RB1 TP53
40
Show member pathways
12.02 CDK2 CDKN1A RBL1 TP53
41 12 CCND1 CDK2 CDK4 CDKN1A MYC RB1
42
Show member pathways
11.96 CCND1 CDK2 CDK4 RB1 RBL1
43 11.94 CDK2 CDK4 CDKN1A CDKN2B MYC RBL1
44 11.93 CDK2 CDKN1A MYC RB1 RBL1
45 11.9 CCND1 CDK2 CDK4 CDKN1A CDKN2A MYC
46